Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) saw unusually-high trading volume on Monday . Approximately 3,496,200 shares were traded during mid-day trading, an increase of 100% from the previous session’s volume of 1,752,250 shares.The stock last traded at $13.1280 and had previously closed at $12.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CLBT shares. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Stock Up 1.9%

The firm has a market cap of $3.29 billion, a P/E ratio of 42.16, a price-to-earnings-growth ratio of 1.99 and a beta of 1.30. The stock’s 50-day moving average is $14.52 and its 200-day moving average is $16.74.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. During the same period in the previous year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently bought and sold shares of CLBT. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Cellebrite DI by 40.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after purchasing an additional 103,568 shares in the last quarter. Norwood Investment Partners LP acquired a new stake in shares of Cellebrite DI during the 3rd quarter worth about $4,274,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Cellebrite DI during the 3rd quarter worth about $19,457,000. Moody National Bank Trust Division bought a new position in Cellebrite DI during the 3rd quarter valued at about $2,670,000. Finally, TimesSquare Capital Management LLC bought a new position in Cellebrite DI during the 3rd quarter valued at about $11,217,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.